A German pet therapeutic start-up, Adivo, has obtained seed funding for an undisclosed amount. The backers include German venture capital firm High-Tech Gründerfonds, Swiss investment business Occident Group and its former parent company MorphoSys. Adivo are making use of a new, fully synthetic phage display antibody library which mimics the canine immune globulin repertoire.